ADHD-RS (ADHD Rating Scale)

The ADHD-RS (ADHD Rating Scale) is a tool used in clinical trials to assess the severity of Attention-Deficit/Hyperactivity Disorder symptoms. While the specific range of the scale is not detailed in the provided definitional facts, it is used to quantify symptom presentation. For inclusion in some studies, a minimum ADHD-RS score at the 90th percentile was required, as seen in the Tris Pharma — Dyanavel Xr FDA Review. Another eligibility criterion noted was a baseline ADHD-RS-5 score of 28 for studies like the Supernus Pharmaceuticals, Inc. — Qelbree FDA Review.

In the regulatory reviews, the ADHD-RS serves as a key endpoint to evaluate treatment efficacy. For instance, the Supernus Pharmaceuticals, Inc. — Qelbree FDA Review reported an ADHD-RS-5 Total Score LS Mean Change from Baseline of -10.6 for White, Placebo. The Ironshore Pharmaceuticals — Jornay Pm FDA Review showed an ADHD-RS-IV total score difference (HLD200 vs placebo) with a p-value of p <0.001. Additionally, the COMMAVE SUB — Azstarys FDA Review utilized an ADHD-RS-5 score reduction of ≥30% for eligibility.